Dupixent Case Acquisition for Law Firms: An Emerging Opportunity Window

Dupixent case acquisition for law firms represents a high-volume, early-stage litigation opportunity in a Dupixent—the IL-4/IL-13 blocking monoclonal antibody developed by Sanofi and Regeneron—is a $14 billion-plus annual revenue blockbuster. It's approved for atopic dermatitis, asthma, nasal polyps, and eosinophilic esophagitis (EoE). It's also generating a wave of post-market adverse event reports that plaintiff attorneys are only now beginning to evaluate seriously. Paradoxical eosinophilia, severe ocular surface disease (conjunctivitis, keratitis, limbal stem cell deficiency, corneal scarring), and paradoxical worsening of the very EoE it treats—these are documented in FAERS, peer-reviewed case series, and FDA label updates. The litigation is in an emerging, pre-MDL stage. No coordinated federal MDL yet. No bellwether trials. No settlement benchmarks. For firms evaluating Dupixent case acquisition for law firms, this is a window: early positioning, high information asymmetry favoring first movers, and a massive exposed population. But timing, channel strategy, intake rigor, and realistic cost-per-case math matter enormously.4 billion annual revenue market with minimal competitive saturation. Sanofi and Regeneron's IL-4/IL-13 blocking monoclonal antibody has generated documented post-market adverse events—paradoxical eosinophilia, severe ocular surface disease, and treatment-resistant EoE—now appearing in FAERS databases and peer-reviewed literature. The litigation remains in pre-MDL stage with no coordinated federal action yet, positioning early-moving firms to build substantial claimant inventories before mass consolidation.

I've overseen $250 million in mass tort ad spend across 600+ plaintiff law firms and 100+ separate torts over 15 years. I've run early-stage campaigns in emerging torts—before MDLs form, before settlement benchmarks exist, when information density is low and first-mover advantage is real. Dupixent is at that inflection point right now. This post walks a firm's decision-making process: the litigation landscape, claimant pool sizing, ad economics, intake rigor, and the operational reality of Dupixent case acquisition for law firms in 2025.

The Litigation Landscape: Pre-MDL Dynamics and What They Mean for Case Value

Dupixent litigation is emerging. As of early 2025, no federal MDL has been coordinated. State court filings are trickling in. FAERS data—particularly since 2021–2022—shows clustering of ocular adverse events and paradoxical eosinophilia. FDA label updates have expanded warnings for conjunctivitis and keratitis. Published case series in peer-reviewed journals document both ocular surface disease and paradoxical eosinophil elevation as causally linked to IL-4/IL-13 blockade. The science is there. The warning failures are documentable. What's missing—and what makes this stage both opportunity and risk—is litigation infrastructure.

For a plaintiff firm evaluating case acquisition right now, the pre-MDL environment means three things:

  • Case value is unstable. Without coordinated discovery, bellwether outcomes, or settlement frameworks, you're building a case portfolio without comparable verdicts or settlement benchmarks. A severe ocular case (corneal scarring, vision loss, surgical intervention) may settle for $100K or $500K depending on state law, judge, jury pool, and defense counsel. This creates pricing uncertainty for your acquisition spend.
  • Discovery advantage is real. Firms filing early and aggressively can lock in favorable discovery plans, depose key Sanofi and Regeneron personnel, and develop fact patterns before the tort becomes crowded. This early-stage leverage translates to stronger settlement posture downstream.
  • Timing of ad spend is critical. If an MDL forms in 2025 or 2026, centralized management may slow individual firm case intake. If you acquire cases now, you capture them before that centralizing event. If you wait, you may be funneling intake into a structured MDL with preset settlement tracks and limited upside leverage.

The question for your firm: are you positioned to build a first-mover discovery portfolio, or are you entering at the tail end? That answer shapes whether Dupixent case acquisition for law firms is a priority or a watch-and-wait bet.

Claimant Pool & Demand: Sizing the Addressable Market

Dupixent is prescribed for four main indications: atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic esophagitis (EoE). Approximately 16–20 million Americans have moderate-to-severe atopic dermatitis. Over 25 million have asthma. Nasal polyps affect millions. EoE is rarer (1–3 per 10,000 in developed countries), but growing in prevalence and diagnosis. Dupixent has captured significant market share in these categories since its 2017 launch and subsequent label expansions.

Not all Dupixent users will experience adverse events. FAERS reports suggest ocular surface disease occurs in a subset—perhaps 1–3% of users, depending on underlying risk factors (pre-existing dry eye, atopy, contact lens use, age). Paradoxical eosinophilia is rarer but well-documented. Paradoxical worsening of EoE is documented in case series but quantitatively unclear.

Conservative math: if 5–7 million Americans have been exposed to Dupixent, and 1–2% experienced actionable adverse events, you're looking at 50,000–140,000 potential claimants. Saturation is low—early case acquisition hasn't saturated the plaintiff bar yet. Geographic concentration follows prescribing patterns: urban dermatology centers, major asthma treatment hubs, gastroenterology centers for EoE. No geographic restriction exists; the drug is available nationwide via major pharmacies and specialty distributors.

For firm-side demand: the pool is large, early saturation is manageable, and geographic targeting is straightforward. Claimants are motivated by visible harm (ocular damage, vision loss, surgical intervention for EoE worsening) and discoverable causation (timing of symptoms post-initiation, medical records documenting adverse events, FAERS data supporting the signal).

Advertising Economics: Cost-Per-Lead and Cost-Per-Signed-Case Reality

For emerging mass torts in the pre-MDL phase, ad economics depend on competitive saturation, claimant awareness, and conversion friction. Dupixent is moderately competitive right now—several plaintiff firms are testing acquisition, but far fewer than you'd see in a mature tort (like talc or hernia mesh).

Cost-Per-Lead (CPL): Realistic range is $35–$85 per qualified lead on Facebook and Google (the primary channels for mass tort acquisition). Why the range? Atopic dermatitis and asthma populations are broad; ocular injury and paradoxical eosinophilia are narrower. Broad targeting (atopic dermatitis patients, asthma patients) yields cheaper leads but lower qualification rates. Narrow targeting (ocular surgery for EoE, corneal damage diagnosis) yields higher CPL but better-qualified intake.

Cost-Per-Signed-Case (CPSC): Figure $2,500–$6,500 per signed case, fully loaded. This includes ad spend, creative production, intake processing, basic qualification, and retainer generation. Firms operating lean processes report closer to $2,500–$3,500. Firms with higher intake friction, longer qualification calls, or lower close rates report $4,500–$6,500.

Channel Strategy: Facebook and Instagram dominate for Dupixent acquisition. Audiences targeting chronic condition management, dermatology interest, and allergy/asthma categories perform well. Google Search is secondary but effective for high-intent users searching "Dupixent side effects," "Dupixent lawsuits," and related keywords. YouTube skippable video ads work for awareness and consideration, not high-intent conversion.

Creative Angles That Convert: The most effective messaging focuses on documented adverse events, not broad injury claims. Examples: "Dupixent and corneal scarring: if you've had eye surgery after Dupixent use," or "Dupixent and eosinophilia: if your condition worsened on treatment." Imagery of medical documentation (eye exams, endoscopy records, ophthalmology notes) outperforms generic "injury" imagery. Testimonial-style creative from actual claimants, if available, converts at 1.5–2x higher rates than institutional messaging. Avoid claimant-facing language entirely; frame the ad message for law-firm-to-claimant lead generation: "Attorneys evaluating Dupixent cases are now accepting intake."

Intake & Qualification: Building Case Stickiness and Screening Rigor

Not every Dupixent exposure generates a case. Your intake process must distinguish between marginal claims and durable ones. Here's the firm-side qualification framework:

Core Eligibility Gates:

  • Causation proximity: Adverse event onset within 6–12 months of Dupixent initiation. Delayed onset (2+ years) weakens failure-to-warn causation. Medical records documenting timing are mandatory.
  • Severity threshold: Ocular cases require documented corneal involvement (keratitis, epithelial defect, scarring, limbal stem cell deficiency), surgical intervention, or documented vision loss. Simple conjunctivitis or dry eye, absent objective findings, is lower value and slower to resolve. EoE cases require documented worsening (increased eosinophil counts, symptom escalation, hospitalizations, endoscopic findings) despite or after Dupixent initiation.
  • Medical documentation: Ophthalmology or gastroenterology records, lab results, imaging, operative notes. Claimants relying on self-reported symptoms or primary-care notes only are slower to qualify and higher friction to retain.
  • Pre-existing condition:** Claimants with pre-existing ocular disease or EoE are tougher cases—the defense will argue underlying condition, not Dupixent. Strongest cases are claimants with new-onset or sharply worsening disease temporally linked to Dupixent initiation.

Retainer Design & Case Stickiness: Dupixent cases are moderately complex, with 12–24 month litigation timelines before settlement feasibility (depending on MDL formation and discovery pace). Your retainer should reflect this: contingent representation with clear communication on discovery process, settlement timeline, and funding mechanisms (if you're advancing costs). Firms using transparent cost-plus retainers—stating upfront that MTAA charges 15% of ad spend plus $X in management fees—report higher case stickiness because expectations are clear from day one. Claimants understand you're running a disciplined acquisition operation, not a charity; professionalism follows.

Ongoing Qualification: First intake call generates a lead. Second call (with medical review partner or in-house paramedic) confirms severity, documentation, and causation proximity. Only after that do you extend a retainer. This two-stage process eliminates 20–30% of marginal leads before you incur full intake processing cost.

How MTAA Structures Dupixent Case Acquisition

We've managed Dupixent acquisition campaigns for 15+ plaintiff firms since early 2024. Our approach reflects 15 years of emerging-tort playbook:

Campaign Architecture: We run multi-channel acquisition (Facebook, Instagram, Google Search, YouTube) with tiered creative: broad awareness at top of funnel (Dupixent adverse events, ocular safety, EoE paradox), mid-funnel consideration (case studies, medical evidence, FAQ), and high-intent conversion (attorney intake portal, lead capture forms, call-now buttons). Budget allocation typically runs 60% Facebook/Instagram, 30% Google Search, 10% YouTube/Display, but we adjust based on firm-specific performance data.

Lead Qualification & Handoff: We screen leads for basic eligibility (Dupixent exposure, adverse event type, geographic jurisdiction) before forwarding to your intake team. This pre-filtering improves your team's efficiency and reduces time-per-intake-call. We also provide weekly reporting: cost-per-lead, cost-per-signed-case, channel performance, and conversion rates by severity tier. You always know ROI.

Pricing: We charge transparent cost-plus: your media spend (Facebook, Google, production) plus 15% management fee. No hidden charges. If you allocate $50K/month to Facebook ads, you pay $50K to Meta plus $7,500 to MTAA (15%). This aligns incentives—we optimize for case quality and cost efficiency, not vanity metrics like lead volume.

Creative Development: We produce custom creative for Dupixent campaigns: short-form testimonial video, carousel ads highlighting adverse events (ocular, EoE paradox), FAQ graphics addressing common concerns, and legal-compliant educational content. All creative undergoes legal review to ensure attorney-side (not claimant-side) framing.

Dupixent Case Acquisition for Law Firms: The Competitive Advantage Window

Here's the strategic reality: the Dupixent window—where case acquisition is relatively uncrowded, where first-mover discovery advantage is real, and where case values remain undefined and potentially high—is closing. In 6–18 months, expect an MDL. Once centralized, your individual case leverage flattens. Now is the time to build a cohesive portfolio of strong Dupixent cases: documented ocular damage, clear causation proximity, clear medical records, diverse severities for negotiating leverage.

Firms that execute disciplined Dupixent case acquisition for law firms campaigns now—targeting specific adverse events, running rigorous intake qualification, and building a 50–200 case portfolio before MDL formation—will have the discovery leverage, settlement positioning, and client relationship depth to negotiate premium outcomes.

Firms that wait risk entering a centralized MDL with preset settlement matrices, limited upside, and structural disadvantage for early movers. The math favors action now.

Close: Positioning Your Firm for Dupixent Opportunity

Dupixent case acquisition for law firms is viable, valuable, and time-sensitive. The claimant pool is large (50,000–140,000 exposed individuals with actionable adverse events). The litigation landscape is emerging (pre-MDL, high first-mover advantage, undiscovered case value). The ad economics are favorable ($35–$85 CPL, $2,500–$6,500 CPSC). The intake framework is clear (severity gates, medical documentation, causation proximity). And the window for independent, high-leverage case building is closing.

If your firm has capacity to acquire 20–50 Dupixent cases over the next 6–12 months, and if you're willing to invest in disciplined intake and early-stage discovery, then Dupixent case acquisition for law firms should be an active strategic priority. At MTAA, we've built the campaign infrastructure to support that—multi-channel acquisition, legal-compliant creative, transparent cost-plus pricing, and ongoing performance reporting—for firms ready to move.

The firms that act on this opportunity now will dominate Dupixent settlement negotiations downstream. The question is whether yours will be one of them.

Ready to Build Your Caseload?

Get a free campaign analysis from Mass Tort Ad Agency.

$250M+ in mass tort Facebook ad spend. 600+ law firms served. Transparent cost-plus pricing with no hidden fees.

Schedule a Free Consultation →

Frequently Asked Questions: Advertising Dupixent Cases

What does it cost a law firm to acquire Dupixent cases?

Acquisition cost depends on the channel, creative, and qualification bar, and is best measured as cost per signed retainer rather than cost per lead. Mass Tort Ad Agency runs these campaigns at ad spend plus a 15% management fee with no hidden markups, so firms see the true per-case economics.

How do plaintiff firms advertise Dupixent cases efficiently?

Most signed volume comes from targeted Facebook and Instagram campaigns paired with a tight intake and qualification process. MTAA manages these end to end across 100+ active mass torts for 600+ firms.